Comerica Bank
GLUE icon

Comerica Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Comerica Bank’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.35K Sell
596
-245
-29% -$3.3K ﹤0.01% 3262
2025
Q3 		$6.23K Hold
841
– – ﹤0.01% 3365
2025
Q2 		$3.79K Hold
841
– – ﹤0.01% 3412
2025
Q1 		$3.9K Sell
841
-268
-24% -$1.64K ﹤0.01% 3363
2024
Q4 		$7.7K Buy
1,109
+268
+32% +$2.01K ﹤0.01% 3232
2024
Q3 		$4.46K Hold
841
– – ﹤0.01% 3363
2024
Q2 		$3.15K Hold
841
– – ﹤0.01% 3390
2024
Q1 		$5.93K Hold
841
– – ﹤0.01% 3300
2023
Q4 		$4.75K Buy
+841
New +$3.3K ﹤0.01% 3333

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Comerica Bank's GLUE Position: Q4 2025 in Review

Comerica Bank reduced its Monte Rosa Therapeutics (GLUE) stake by 29% in Q4 2025, selling an estimated $3.3K and leaving 596 shares worth $9.35K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

Comerica Bank first reported a position in GLUE in Q4 2023 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Comerica Bank held 596 shares of Monte Rosa Therapeutics worth $9.35K as of Q4 2025.
  • Comerica Bank sold 245 Monte Rosa Therapeutics shares in Q4 2025, an estimated $3.3K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3262 holding.
  • Comerica Bank first reported a position in Monte Rosa Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.